Literature DB >> 18787622

Perivascular neuritic dystrophy associated with cerebral amyloid angiopathy in Alzheimer's disease.

Kenichi Oshima1, Hirotake Uchikado, Dennis W Dickson.   

Abstract

Cerebral amyloid angiopathy (CAA) affects both leptomeningeal and parenchymal blood vessels and is common in Alzheimer's disease (AD). In some vessels, CAA is accompanied by localized neuritic dystrophy around the affected blood vessel. The aim of this study was to assess the distribution and severity of perivascular neuritic dystrophy in primary visual and visual association cortices. The severity of perivascular neuritic dystrophy and Abeta deposition was scored in an association cortex (Brodmann area 18) and a primary cortex (Brodmann area 17) with double labeling immunohistochemistry for tau and Abeta in 31 cases of AD with severe CAA. The perivascular tau neuritic dystrophy score was significantly worse in visual association cortex than in primary visual cortex. On the other hand, there was no difference in the perivascular Abeta score between the two cortices. There were positive correlations between the severity of perivascular tau and perivascular Abeta scores for both primary and association cortices. The results suggest that the local neuronal environment determines the severity and nature of the perivascular neuritic pathology more than the severity of the intrinsic vascular disease and suggest a close association between perivascular amyloid deposits, so-called dyshoric angiopathy, and perivascular neuritic dystrophy.

Entities:  

Keywords:  Alzheimer's disease; Aβ; amyloid angiopathy; neuritic dystrophy; tau; visual cortex

Year:  2008        PMID: 18787622      PMCID: PMC2480573     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  14 in total

1.  Observation of morphological relationships between angiopathic blood vessels and degenerative neurites in Alzheimer's disease.

Authors:  A Delacourte; A Defossez; P Persuy; M C Peers
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

2.  Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease.

Authors:  S Williams; K Chalmers; G K Wilcock; S Love
Journal:  Neuropathol Appl Neurobiol       Date:  2005-08       Impact factor: 8.090

3.  Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms.

Authors:  Johannes Attems
Journal:  Acta Neuropathol       Date:  2005-09-17       Impact factor: 17.088

4.  Visual association pathology in preclinical Alzheimer disease.

Authors:  Ann C McKee; Rhoda Au; Howard J Cabral; Neil W Kowall; Sudha Seshadri; Caroline A Kubilus; Jon Drake; Philip A Wolf
Journal:  J Neuropathol Exp Neurol       Date:  2006-06       Impact factor: 3.685

5.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

6.  Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person.

Authors:  P Delaère; C Duyckaerts; C Masters; K Beyreuther; F Piette; J J Hauw
Journal:  Neurosci Lett       Date:  1990-08-14       Impact factor: 3.046

Review 7.  The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies.

Authors:  B T Hyman
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

8.  Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.

Authors:  Salvatore Oddo; Lauren Billings; J Patrick Kesslak; David H Cribbs; Frank M LaFerla
Journal:  Neuron       Date:  2004-08-05       Impact factor: 17.173

9.  Progression of Alzheimer histopathological changes.

Authors:  C Duyckaerts; M A Colle; F Dessi; F Piette; J J Hauw
Journal:  Acta Neurol Belg       Date:  1998-06       Impact factor: 2.396

10.  Identification of normal and pathological aging in prospectively studied nondemented elderly humans.

Authors:  D W Dickson; H A Crystal; L A Mattiace; D M Masur; A D Blau; P Davies; S H Yen; M K Aronson
Journal:  Neurobiol Aging       Date:  1992 Jan-Feb       Impact factor: 4.673

View more
  12 in total

1.  APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics.

Authors:  M P Vitek; D J Christensen; D Wilcock; J Davis; W E Van Nostrand; F Q Li; C A Colton
Journal:  Neurodegener Dis       Date:  2012-02-09       Impact factor: 2.977

2.  Early-onset formation of parenchymal plaque amyloid abrogates cerebral microvascular amyloid accumulation in transgenic mice.

Authors:  Feng Xu; AnnMarie E Kotarba; Ming-Hsuan Ou-Yang; Ziao Fu; Judianne Davis; Steven O Smith; William E Van Nostrand
Journal:  J Biol Chem       Date:  2014-05-14       Impact factor: 5.157

3.  Non-neuronal and neuronal BACE1 elevation in association with angiopathic and leptomeningeal β-amyloid deposition in the human brain.

Authors:  Zhi-Qin Xue; Zheng-Wen He; Jian-Jun Yu; Yan Cai; Wen-Ying Qiu; Aihua Pan; Wei-Ping Gai; Huaibin Cai; Xue-Gang Luo; Chao Ma; Xiao-Xin Yan
Journal:  BMC Neurol       Date:  2015-05-02       Impact factor: 2.474

4.  Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy.

Authors:  Laura J Blair; Haley D Frauen; Bo Zhang; Bryce A Nordhues; Sara Bijan; Yen-Chi Lin; Frank Zamudio; Lidice D Hernandez; Jonathan J Sabbagh; Maj-Linda B Selenica; Chad A Dickey
Journal:  Acta Neuropathol Commun       Date:  2015-01-31       Impact factor: 7.801

5.  Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer's disease-related microvascular cerebral amyloid angiopathy.

Authors:  Mario Merlini; Debora Wanner; Roger M Nitsch
Journal:  Acta Neuropathol       Date:  2016-03-17       Impact factor: 17.088

6.  Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine?

Authors:  Jian-Ming Li; Li-Ling Huang; Fei Liu; Bei-Sha Tang; Xiao-Xin Yan
Journal:  BMC Neurol       Date:  2017-08-25       Impact factor: 2.474

7.  Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy.

Authors:  Yingjian You; Abigail Perkins; Pablo Cisternas; Braulio Muñoz; Xavier Taylor; Yanwen You; Holly J Garringer; Adrian L Oblak; Brady K Atwood; Ruben Vidal; Cristian A Lasagna-Reeves
Journal:  Acta Neuropathol Commun       Date:  2019-02-26       Impact factor: 7.801

Review 8.  The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy.

Authors:  Pablo Cisternas; Xavier Taylor; Cristian A Lasagna-Reeves
Journal:  Int J Mol Sci       Date:  2019-12-14       Impact factor: 5.923

9.  mNos2 deletion and human NOS2 replacement in Alzheimer disease models.

Authors:  Carol A Colton; Joan G Wilson; Angela Everhart; Donna M Wilcock; Jukka Puoliväli; Taneli Heikkinen; Juho Oksman; Olli Jääskeläinen; Kimmo Lehtimäki; Teemu Laitinen; Nina Vartiainen; Michael P Vitek
Journal:  J Neuropathol Exp Neurol       Date:  2014-08       Impact factor: 3.685

Review 10.  The neuropathological diagnosis of Alzheimer's disease.

Authors:  Michael A DeTure; Dennis W Dickson
Journal:  Mol Neurodegener       Date:  2019-08-02       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.